SCHEMBL2490237

SCHEMBL2490237

CCCCc1ccccc1[CH]c1ccccc1CCCC

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
LIPG Q9Y5X9 1/20 0.46
TLR8 Q9NR97 2/20 0.40
TYR P14679 1/20 0.38
THRA P10827 1/20 0.38
THRB P10828 1/20 0.38
NR1H2 P55055 1/20 0.38
NR1H3 Q13133 1/20 0.38
ALOX5 P09917 1/20 0.37
PTGS2 P35354 1/20 0.37
MITF O75030 1/20 0.36
CTRC Q99895 1/20 0.35
BID P55957 2/20 0.35
BCL2L1 Q07817 2/20 0.35
MCL1 Q07820 2/20 0.35
BAK1 Q16611 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2494577 0.86 MITF (0.38) CYP3A4CYP2D6CYP2C9LIPGMITF
SCHEMBL11260116 0.85 CYP3A4 (0.45) CYP3A4CYP2D6CYP2C9LIPGTLR8
SCHEMBL2921344 0.85 CYP3A4 (0.45) CYP3A4CYP2D6CYP2C9LIPGTLR8
SCHEMBL4952213 0.83 CYP3A4 (0.44) CYP3A4CYP2D6CYP2C9LIPGTLR8
SCHEMBL266417 0.83 LIPG (0.47) CYP3A4CYP2D6CYP2C9LIPGTLR8
SCHEMBL22401086 0.83 CYP3A4 (0.47) CYP3A4CYP2D6CYP2C9LIPGTLR8
SCHEMBL28869 0.83 CYP3A4 (0.44) CYP3A4CYP2D6CYP2C9LIPGTLR8
SCHEMBL29480441 0.83 CYP3A4 (0.44) CYP3A4CYP2D6CYP2C9LIPGTLR8
SCHEMBL31094907 0.82 CYP3A4 (0.42) CYP3A4CYP2D6CYP2C9LIPGTLR8
SCHEMBL31734211 0.82 LIPG (0.46) CYP3A4CYP2D6CYP2C9LIPGTLR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2380567-B1 MELANIN PRODUCTION INHIBITOR POLA CHEM IND INC (JP) 2019-01-16 EP disclosed
EP-3009123-A1 MELANIN PRODUCTION INHIBITOR Pola Chemical Industries Inc. (JP) 2016-04-20 EP disclosed
US-20150328107-A1 MELANIN PRODUCTION INHIBITOR POLA CHEMICAL INDUSTRIES INC. (JP) 2015-11-19 US disclosed
EP-2845587-A2 Melanin production inhibitor Pola Chemical Industries Inc. (JP) 2015-03-11 EP disclosed
US-20140363389-A1 MELANIN PRODUCTION INHIBITOR POLA CHEMICAL INDUSTRIES INC. (JP) 2014-12-11 US disclosed
US-8846012-B2 Melanin production inhibitor POLA CHEMICAL INDUSTRIES INC. (JP) 2014-09-30 US disclosed
EP-2380567-A1 MELANIN PRODUCTION INHIBITOR Pola Chemical Industries Inc. (JP) 2011-10-26 EP disclosed
US-20110243865-A1 MELANIN PRODUCTION INHIBITOR POLA CHEMICAL INDUSTRIES INC. (JP) 2011-10-06 US disclosed
US-20070189058-A1 Molecular system and method for reversibly switching the same between four states HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. 2007-08-16 US disclosed
US-20070112103-A1 Molecular system and method for reversibly switching the same HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. 2007-05-17 US disclosed
EP-0600084-A1 INDOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1994-06-08 EP disclosed
US-5312829-A Testosterone 5alpha-reductase inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1994-05-17 US disclosed
US-5283251-A Testosterone 5a-reductase inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1994-02-01 US disclosed
WO-1993013099-A1 ARYL KETONES AS TESTOSTERONE 5α-REDUCTASE INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1993-07-08 WO disclosed
US-5212320-A Enzyme inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1993-05-18 US disclosed
WO-1993003012-A1 INDOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1993-02-18 WO disclosed
EP-0519353-A2 Indolizin derivatives, process for their preparation and pharmaceutical composition containing them FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1992-12-23 EP disclosed
EP-0516849-A1 INDOLE DERIVATIVES. FUJISAWA PHARMACEUTICAL CO (JP) 1992-12-09 EP disclosed
EP-0458207-A2 Indole derivatives FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1991-11-27 EP disclosed
WO-1991013060-A1 INDOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1991-09-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110243865-A1 MELANIN PRODUCTION INHIBITOR TYR, F12, TH CYP3A4 115/4885CYP2D6 141/4885CYP2C9 19/4885
US-20150328107-A1 MELANIN PRODUCTION INHIBITOR TYR, MC1R, F12 CYP3A4 106/4885CYP2D6 116/4885CYP2C9 21/4885
US-20140363389-A1 MELANIN PRODUCTION INHIBITOR TYR, F12, MC1R CYP3A4 104/4885CYP2D6 137/4885CYP2C9 23/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.